Stoked Bio Inc. Deal History & Licensing Activity
Stoked Bio Inc. is a life sciences. Over the past three years, Stoked Bio Inc. has been involved in 2 licensing and acquisition transactions, with a primary focus on Small Molecules (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Small Molecules
Focus Area
Immunology
Stoked Bio Inc. Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Stoked Bio Inc. in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| enterololin | McMaster University | Small Molecules | Unknown | license | Feb 2026 |
| Zorevunersens | Biogen | Oligonucleotides | Preclinical | license | Jun 2025 |
Stoked Bio Inc. Pipeline Focus
Therapeutic areas and modalities where Stoked Bio Inc. is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Stoked Bio Inc. Strategic Signals
Key indicators of Stoked Bio Inc.'s licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Stoked Bio Inc.'s Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Immunology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Oligonucleotides Benchmarks
Upfront, milestone, and royalty benchmarks for oligonucleotides deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Stoked Bio Inc. Licensing & Deal Activity
Stoked Bio Inc. is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Stoked Bio Inc. ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Stoked Bio Inc. include Immunology (2 deals and trials), and Neurology (2 deals and trials). In terms of modality, Stoked Bio Inc. has shown particular interest in small molecules, oligonucleotides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Stoked Bio Inc. and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Stoked Bio Inc.'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.